Actively Recruiting
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
Led by Nanfang Hospital, Southern Medical University · Updated on 2021-02-09
3000
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new concept proposed in 2020. Unlike non-alcoholic fatter liver disease (NAFLD), the diagnosis of MAFLD requires the presence any of the following 3 metabolic risks, including overweight/obesity, presence of diabetes mellitus, and evidence of metabolic dysregulation. However, there are patients that have hepatic steatosis but no metabolic risk, who thus do not meet the diagnostic criteria of MAFLD. Besides, there are patients with both MAFLD and other liver diseases. The clinical features and the management of these patients remain unclear. Thus, further histopathological and clinical study is required to elucidate and compare the characteristics of MAFLD and NAFLD. Here, in this single-center, prospective clinical study, investigators are planning to establish a long-term follow-up cohort of patients with either MAFLD or NAFLD. In order to understand the risk of developing liver-related complications and important extra-hepatic outcomes (e.g. cardiovascular disease), and also to better elucidate the risk of disease progression in "lean" NAFLD individuals without any metabolic dysregulation and MAFLD individuals with dual or multiple causes. Ultimately, investigators aim to improve the diagnosis of MAFLD and improve patients' outcomes.
CONDITIONS
Official Title
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hepatic steatosis as an adult by at least one of the following: liver ultrasound showing bright liver, controlled attenuation-parameter (CAP) 6248 dB/m, diagnosis by CT/MRI/MRS, MRI-based proton-density fat fraction over 8%, or liver biopsy confirming fatty liver
You will not qualify if you...
- Diagnosed with hepatocellular carcinoma or other malignancy
- Currently pregnant
- History of liver transplantation
- History of serious cardiovascular or cerebrovascular events such as acute myocardial infarction, cerebral infarction, or cerebral hemorrhage
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
J
Jinjun Chen
CONTACT
L
Ling Zhou
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here